|
|
|
|
Medicinski pregled 2002, vol. 55, br. 7-8, str. 286-292
|
|
|
Uticaj terapije ramiprilom na pojedine komponente sindroma insulinske rezistencije u bolesnika sa esencijalnom hipertenzijom
aUniverzitet u Kragujevcu, Medicinski fakultet bUniverzitet u Beogradu, Medicinski fakultet, Klinički centar Srbije
e-adresa: ljbojovic@hotmail.com
SažetakEsencijalna hipertenzija predstavlja komponentu sindroma insulinske rezistencije. Insulinska rezistencija se definiše kao stanje u kome insulin ostvaruje manji odgovor od očekivanog, biološkog odgovora. Prospektivnom kliničkom studijom analizirano je 15 bolesnika (7 muškaraca i 8 žena), sa normalnom glikoznom tolerancijom prosečne starosti 53,24 ± 6,60 godina, sa BMI 26,97 ± 1,24 kg/m2, sa blagom ili umerenom esencijalnom hipertenzijom pre i posle primene ramiprila u trajanju od 12 nedelja. Za procenu periferne insulinske senzitivnosti i glikozne efektivnosti izvođen je Bergmanov test minimalnog modela sa redukovanim brojem uzoraka. Indeks insulinske senzitivnosti u 12. nedelji povećan za 50%, ali nisu dostignute normalne vrednosti za referentni model (Si = 1,22 ± 0,66 vs 1,78 ± 0,8 x 10-4 min/µU/ml). Vrednosti glikozne efektivnosti, lipida i elektrolita plazme ostale su relativno nepromenjene, dok su vrednosti hemoglobina i broja trombocita značajno smanjene. Zbog metaboličke neutralnosti i antitrombotične aktivnosti, ramipril se preporučuje bolesnicima sa hipertenzijom i insulinskom rezistencijom, posebno sa dijabetesom.
Ključne reči
|
|
|
|
Reference
|
|
  1
|
Baba, T., Neugebauer, S. (1994) The link between insulin resistance and hypertension: Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity. Drugs, 47(3): 383-404
|
|
|
Barbieri, M., Ragno, E., Benvenuti, E., Zito, G.A., Corsi, A., Ferrucci, L., Paolisso, G. (2001) New aspects of the insulin resistance syndrome: Impact on haematological parameters. Diabetologia, 44(10): 1232-7
|
|
13
|
de Fronzo, R.A., Ferrannini, E. (1991) Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14(3): 173-94
|
|
|
Doggrell, S.A. (2001) Is ramipril the pril for diabetes and kidney disease. Drugs Today (Barc), 34:321-31
|
|
|
Erlich, Y., Rosenthal, T. (1995) Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Clin Exp Pharmacol Physiol Suppl, 22(1): S347-9
|
|
|
Harano, Y., Suzuki, M., Shinozaki, K., Hara, Y., Ryomoto, K., Kanazawa, A., Nishioheda, Y., Tsushima, M. (1996) Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach. Hypertens Res, 19 Suppl 1: S81-5
|
|
|
Heinig, R.E. (2002) What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. Diabetes Obes Metab, 4 Suppl 1: S19-25
|
|
|
Isles, C.G., Paterson, J.R. (2000) Identifying patients at risk for coronary heart disease: Implications from trials of lipid-lowering drug therapy. QJM, 93(9): 567-74
|
|
|
Krutzfeldt, J., Raasch, W., Klein, H.H. (2000) Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol, 362(1): 1-6
|
|
1
|
Lithell, H.O. (1996) Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens, 9(11): 150S-154S
|
|
|
Ludvik, B., Kueenburg, E., Brunnbauer, M., Schernthaner, G., Prager, R. (1991) The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. J Cardiovasc Pharmacol, 18 Suppl 2: S157-9
|
|
|
Prisant, L.M., Carr, A.A. (1992) Antihypertensive drug therapy and insulin resistance. Am J Hypertens, 5(10): 775-7
|
|
|
Sidani, M., Halter, J., Suplano, M. (1994) Improved glucose tolerance due to enhanced glucose effectiveness in older hypertensives treated with the angiotensin converting enzyme inhibitor ramipril. Clinical Res, 42:117A
|
|
|
Skowasch, D., Lentini, S., Andrie, R., i dr. (2001) Decreased platelet aggregation with angiotensin covering enzyme inhibitor medication: Results of a pilot study. Dtsch Med Wochenschr, 126:707-11
|
|
|
Steil, G.M., Volund, A., Kahn, S.E., Bergman, R.N. (1993) Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model. Suitability for use in population studies. Diabetes, 42(2): 250-6
|
|
|
Timar, O., Sestier, F., Levy, E. (2000) Metabolic syndrome X: A review. Can J Cardiol, 16(6): 779-89
|
|
|
Valensi, P., Derobert, E., Genthon, R., Riou, J.P. (1996) Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp. Diabetes Metab, 22(3): 197-200
|
|
|
Vitovec, J., Spinar, J. (1998) The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus. Vnitr Lek, 44(6): 336-41
|
|
|
Weston, P.J. (2000) Insulin resistance and hypertension: Is impaired arterial baroreceptor sensitivity the missing link?. Clin Sci (Lond), 98(2): 125-6
|
|
|
Yokota, C., Ikebuchi, M., Suzuki, M., Norioka, M., Ikeda, K., Shinozaki, K., Harano, Y. (1995) Insulin resistance rather than hyperinsulinemia more closely associated with essential hypertension. Clin Exp Hypertens, 17(3): 523-36
|
|
|
|
|